What is it about?
Does being a carrier of apolipoprotein E4 (APOE4) affect driving performance? This paper examines the simulated driving of carriers and matched non-carriers of APOE4 with amnestic mild cognitive impairment (aMCI) or Alzheimer's disease dementia (ADD). All participants were regular drivers, who drove in moderate and high traffic volume in a rural environment. We measured driving speed, distance from the vehicle ahead, car position from the right road border, and speed of braking in unexpected incidents.
Featured Image
Why is it important?
The driving behavior of APOE4 carriers compared to non-carriers is not known. Carriers of APOE4 showed less variability than non-carriers in their driving speed but did not differ in any other measures. Reduced speed variability indicates reduced speed adaptations to the driving environment.
Perspectives
Discussing the data with my co-authors was very thought-provoking as the results were in an unexpected direction. The collaboration of colleagues from diverse but complementary backgrounds has been very important in addressing the multidisciplinary topic of simulated driving in neurological disorders.
Alexandra Economou
National and Kapodistrian University of Athens
Read the Original
This page is a summary of: Effect of Apolipoprotein E4 on the Driving Behavior of Patients with Amnestic Mild Cognitive Impairment or Mild Alzheimer’s Disease Dementia, Journal of Alzheimer’s Disease, November 2021, IOS Press,
DOI: 10.3233/jad-210622.
You can read the full text:
Contributors
The following have contributed to this page
